Agios Pharma (AGIO) Misses Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Agios Pharma (AGIO) PT Raised to $55 at RBC Capital
August 2, 2024 6:21 AM EDTRBC Capital analyst Kennen MacKay raised the price target on Agios Pharma (NASDAQ: AGIO) to $55.00 (from $53.00) while maintaining a Outperform rating.
The analyst comments "AGIO reported its 2Q24 update concurrent with the ACTIVATE-KidsT (pediatric PKD) topline results which missed the prespecified... More



